(GOOG) -backed life sciences firm, emerged further from stealth mode Wednesday by announcing a drug development collaboration with pharmaceuticals giant
(ABBV - Get Report) .
Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer. Calico will set up an R&D facility in the San Francisco Bay Area, and each company will contribute $250 million in initial funding. The funding commitment could grow to $1.5 billion total over 10 years, the companies said.
Google created Calico as an experimental healthcare skunk works seeking to discover and develop ground-breaking therapies for age-related diseases. Calico has operated largely in stealth mode, except for the hiring of some big-name biotech talent. Former Genentech CEO Art Levinson (a Google board member) was tapped as Calico's CEO. Levinson then brought in Hal Barron, the former chief medical officer at Genentech, as his lieutenant.
Under the collaboration with Abbvie, Calico will be responsible for drug discovery and early clinical development of promising drug candidates. Abbvie will support this early research then has the rights to take over clinical development if drug candidates progress to late-stage studies and commercialization.
04/16/15 - 09:07 AM EDT
04/15/15 - 11:35 AM EDT
04/07/15 - 08:02 AM EDT
04/01/15 - 09:30 AM EDT
03/31/15 - 11:30 AM EDT
04/18/15 - 13:33 PM EDT
04/17/15 - 16:51 PM EDT
04/17/15 - 10:09 AM EDT
04/17/15 - 08:37 AM EDT
04/17/15 - 06:03 AM EDT
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.